Gut microbiome modulates efficacy of immune checkpoint inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Metabolic byproducts of gut microbiota are perceived by cells and molecules of the immune system and modulate the equilibrium between pro- and antitumor functions.
“In conclusion, in view of the metabolic function elicited by gut microbiota, we infer that their metabolic byproducts are perceived by cells and molecules of the immune system and modulate the equilibrium between pro- and antitumor functions.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
Some gut bacteria act as suppressors of inhibitory signal pathways, facilitate antigen presentation, and improve specific antitumor immunity.
“Some gut bacteria act as suppressors of inhibitory signal pathways, facilitate antigen presentation, and improve specific antitumor immunity (118).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
The influence of gut microbiota on host immunity is multifaceted, simultaneously regulating the gut mucosal immune system and the systemic immune system.
“The influence of gut microbiota on host immunity is multifaceted, simultaneously regulating the gut mucosal immune system and systemic immune system (Fig. 2d) [307–310].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · see citing works
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413 · see citing works
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · see citing works
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 15× · see citing works
“The fecal microbiome transplantation in mice supported the conclusions aforementioned [11].”
BackgroundMethodResultInfluentialSokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413 · see citing works
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · see citing works
Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works
Induction of Colonic Regulatory T Cells by Indigenous <i>Clostridium</i> Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752 · see citing works
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 10× · see citing works
“Parabacteroides merdae Human a) Related with enhanced efficacy of PD-1 blockade b) Leading to decreased peripherally derived Treg Matson V 2018 [69]”
BackgroundInfluentialAn Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., & Kasper, D. L. (2005) · Cell · doi:10.1016/j.cell.2005.05.007 · Cited by 2,910 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256 · see citing works
Shotgun metagenomics, from sampling to analysis
Quince, C., Walker, A. W., Simpson, J. T., Loman, N. J., & Segata, N. (2017) · Nature Biotechnology · doi:10.1038/nbt.3935 · Cited by 2,202 · see citing works
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · see citing works
The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon
Donohoe, D. R., Garge, N., Zhang, X., Sun, W., O'Connell, T. M., Bunger, M. K., & Bultman, S. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.018 · Cited by 2,003 · cited 1× · see citing works
“bacterial metabolites, such as SCFAs, can be utilized by intestinal epithelial cells as source of energy [97, 98].”
BackgroundCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · see citing works
Innate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921 · see citing works
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · see citing works
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · see citing works
Microbes in Gastrointestinal Health and Disease
Neish, A. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.10.080 · Cited by 1,388 · see citing works
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · see citing works
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works
T cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,190 · see citing works
Induction and molecular signature of pathogenic TH17 cells
Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D. A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2416 · Cited by 1,174 · see citing works
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970 · see citing works
Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968 · see citing works
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 950 · see citing works
Commensal bacteria at the interface of host metabolism and the immune system
Brestoff, J. R., & Artis, D. (2013) · Nature Immunology · doi:10.1038/ni.2640 · Cited by 945 · see citing works
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · see citing works
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883 · see citing works
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858 · see citing works
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · see citing works
Antibiotic use and its consequences for the normal microbiome
Blaser, M. J. (2016) · Science · doi:10.1126/science.aad9358 · Cited by 836 · see citing works
Microbes, Microbiota, and Colon Cancer
Sears, C. L., & Garrett, W. S. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.007 · Cited by 820 · see citing works
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 786 · see citing works
Tlaskalová‐Hogenová, H., Štëpánková, R., Hudcovic, T., Tučková, L., Cukrowská, B., Lodinová‐Žádníková, R., Kozáková, H., Rossmann, P., Bártová, J., Sokol, D., et al. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.02.005 · Cited by 755 · see citing works
Human Gut Microbiome: Function Matters
Heintz‐Buschart, A., & Wilmes, P. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.11.002 · Cited by 747 · see citing works
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · see citing works
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 646 · see citing works
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 633 · see citing works
Resistance to PD1/PDL1 checkpoint inhibition
O’Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 573 · see citing works
Gut Microbiota, Inflammation, and Colorectal Cancer
Brennan, C. A., & Garrett, W. S. (2016) · Annual Review of Microbiology · doi:10.1146/annurev-micro-102215-095513 · Cited by 572 · see citing works
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538 · see citing works
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529 · see citing works
An enteric virus can replace the beneficial function of commensal bacteria
Kernbauer, E., Ding, Y., & Cadwell, K. (2014) · Nature · doi:10.1038/nature13960 · Cited by 513 · see citing works
Hirota, K., Turner, J.-E., Villa, M., Duarte, J. H., Demengeot, J., Steinmetz, O. M., & Stockinger, B. (2013) · Nature Immunology · doi:10.1038/ni.2552 · Cited by 509 · see citing works
The microbiome and rheumatoid arthritis
Scher, J. U., & Abramson, S. B. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.121 · Cited by 479 · see citing works
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465 · see citing works
Immunological Consequences of Intestinal Fungal Dysbiosis
Wheeler, M. L., Limon, J. J., Bar, A. S., Leal, C. A., Gargus, M. D., Tang, J., Brown, J. S., Funari, V. A., Wang, H. L., Crother, T. R., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.003 · Cited by 418 · see citing works
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 373 · see citing works
Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism
Mao, K., Baptista, A. P., Tamoutounour, S., Zhuang, L., Bouladoux, N. J., Martins, A. J., Huang, Y., Gerner, M. Y., Belkaid, Y., & Germain, R. N. (2018) · Nature · doi:10.1038/nature25437 · Cited by 355 · see citing works
Microbiome-modulated metabolites at the interface of host immunity
Blacher, E., Levy, M., Tatirovsky, E., & Elinav, E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601247 · Cited by 354 · see citing works
Mouse models in oncoimmunology
Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.91 · Cited by 351 · see citing works
Ecological Physiology of Diet and Digestive Systems
Karasov, W. H., del Rio, C. M., & Caviedes‐Vidal, E. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142152 · Cited by 348 · see citing works
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K. M., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 346 · see citing works
Ma, W., Gilligan, B. M., Yuan, J. D., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 328 · see citing works
Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204853 · Cited by 323 · see citing works
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 312 · see citing works
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306 · see citing works
Self-citationMicrobiota, Disease, and Back to Health: A Metastable Journey
Blumberg, R. S., & Powrie, F. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004184 · Cited by 279 · see citing works
The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity
Tai, N., Wong, F. S., & Li, W. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9309-0 · Cited by 254 · see citing works
Resurrection of endogenous retroviruses in antibody-deficient mice
Young, G. R., Eksmond, U., Salcedo, R., Alexopoulou, L., Stoye, J. P., & Kassiotis, G. (2012) · Nature · doi:10.1038/nature11599 · Cited by 215 · see citing works
Haanen, J. B. A. G., & Robert, C. (2015) · Progress in tumor research · doi:10.1159/000437178 · Cited by 214 · see citing works
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 186 · see citing works
Anti‐CD73 therapy impairs tumor angiogenesis
Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171 · see citing works
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Peters, S., Kerr, K. M., & Stahel, R. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.002 · Cited by 157 · see citing works
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 151 · see citing works
Self-citationMullins, I. M., Slingluff, C. L., Lee, J. K., Garbee, C. F., Shu, J., Anderson, S. G., Mayer, M. E., Knaus, W. A., & Mullins, D. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2059 · Cited by 150 · see citing works
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 136 · see citing works
The microbiome and its potential as a cancer preventive intervention
Bultman, S. J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.001 · Cited by 134 · see citing works
Terp, M. G., Olesen, K. A., Arnspang, E. C., Lund, R. R., Lagerholm, B. C., Ditzel, H. J., & Leth‐Larsen, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301274 · Cited by 133 · see citing works
The microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 133 · see citing works
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 118 · see citing works
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 116 · see citing works
Self-citationPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 109 · see citing works
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 106 · see citing works
Dietary Modification of the Intestinal Microbiota
Mai, V. (2004) · Nutrition Reviews · doi:10.1111/j.1753-4887.2004.tb00045.x · Cited by 86 · see citing works
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L. P., & Gajewski, T. F. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 86 · see citing works
Clinical applications of PD-L1 bioassays for cancer immunotherapy
Liu, D., Wang, S., & Bindeman, W. E. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0479-y · Cited by 86 · see citing works
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
Jacquelot, N., Enot, D. P., Flament, C., Vimond, N., Blattner, C., Pitt, J. M., Yamazaki, T., Roberti, M. P., Daillère, R., Vétizou, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80071 · Cited by 77 · see citing works
Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis
Wang, L., Tang, S., Wang, Y., Xu, S., Yu, J., Zhi, X., Ou, Z., Yang, J., Zhou, P., & Shao, Z. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9571-z · Cited by 75 · see citing works
Gastrointestinal Microbiota and Colon Cancer
Hold, G. L. (2016) · Digestive Diseases · doi:10.1159/000443358 · Cited by 73 · see citing works
The Multibiome: The Intestinal Ecosystem's Influence on Immune Homeostasis, Health, and Disease
Filyk, H. A., & Osborne, L. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.007 · Cited by 70 · see citing works
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70 · see citing works
Hefazi, M., Patnaik, M. M., Hogan, W. J., Litzow, M. R., Pardi, D. S., & Khanna, S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.08.016 · Cited by 66 · see citing works
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Liu, S. M., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0506-z · Cited by 63 · see citing works
Botticelli, A., Zizzari, I. G., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12985 · Cited by 56 · see citing works
Human Microbiome Acquisition and Bioinformatic Challenges in Metagenomic Studies
D’Argenio, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020383 · Cited by 56 · see citing works
Immunotherapy Not Working? Check Your Microbiota
West, N. R., & Powrie, F. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.010 · Cited by 54 · see citing works
A Transendocytosis Perspective on the CD28/CTLA-4 Pathway
Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 41 · see citing works
Goel, G., & Sun, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0185-6 · Cited by 32 · see citing works
Dietary Modification of the Intestinal Microbiota
Mai, V. (2004) · Nutrition Reviews · doi:10.1301/nr2004.jun235-242 · Cited by 32 · see citing works
Carpenter, M. R., Rozovsky, S., & Boyd, E. F. (2015) · Journal of Bacteriology · doi:10.1128/jb.00704-15 · Cited by 27 · see citing works
Ozaki, Y., Shindoh, J., Miura, Y., Nakajima, H., Oki, R., Uchiyama, M., Masuda, J., Kinowaki, K., Kondoh, C. N., Tanabe, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3785-4 · Cited by 25 · see citing works
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Carbonnel, F., Soularue, É., Coutzac, C., Chaput, N., Mateus, C., Lepage, P., & Robert, C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0613-x · Cited by 24 · see citing works
Microbiote intestinal et réponses aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2016) · médecine/sciences · doi:10.1051/medsci/20163211013 · Cited by 21 · see citing works
Irrazábal, T., & Martín, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0987 · Cited by 13 · see citing works
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Lu, J., & Ramirez, R. A. (2017) · PubMed Central · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works
Self-citationBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 756 · see citing works
Self-citationRegulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works
Self-citationRNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L., Huang, X., Huang, S., Xie, S., Xiao, Z., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 600 · see citing works
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 449 · see citing works
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413 · see citing works
Self-citationNext generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 265 · see citing works
Self-citationLee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217 · see citing works
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 203 · see citing works
Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases
Effendi, R. M. R. A., Anshory, M., Kalim, H., Dwiyana, R. F., Suwarsa, O., Pardo, L. M., Nijsten, T. E. C., & Thio, H. B. (2022) · Microorganisms · doi:10.3390/microorganisms10122382 · Cited by 190 · see citing works
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164 · see citing works
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161 · see citing works
<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works
Self-citationHu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32960-3 · Cited by 155 · see citing works
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153 · see citing works
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 143 · see citing works
Shi, L., Sheng, J., Chen, G., Zhu, P., Shi, C., Li, B., Park, C., Wang, J., Zhang, B., Liu, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000973 · Cited by 134 · see citing works
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 133 · see citing works
Self-citationPredictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 125 · see citing works
Self-citationAdvances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117 · see citing works
Self-citationGut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115 · see citing works
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, J., Chehrazi‐Raffle, A., Placencio-Hickok, V., Guan, M., Hendifar, A. E., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 113 · see citing works
Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 102 · see citing works
Unexpected therapeutic effects of cisplatin
Raudenská, M., Balvan, J., Fojtů, M., Gumulec, J., & Masařík, M. (2019) · Metallomics · doi:10.1039/c9mt00049f · Cited by 104 · see citing works
Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 99 · see citing works
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martı́n-Castillo, B., & Menéndez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 99 · see citing works
Intestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98 · see citing works
The Gut Microbiome and Female Health
Siddiqui, R., Makhlouf, Z., Alharbi, A. M., Alfahemi, H. H., & Khan, N. A. (2022) · Biology · doi:10.3390/biology11111683 · Cited by 101 · see citing works
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96 · see citing works
Self-citationTGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 94 · see citing works
Self-citationThe Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
Aarnoutse, R., Ziemons, J., Penders, J., Rensen, S. S., de Vos‐Geelen, J., & Smidt, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174145 · Cited by 84 · see citing works
Intratumor microbiome in cancer progression: current developments, challenges and future trends
Liu, J., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00381-5 · Cited by 84 · see citing works
Liu, J., Chen, C., Wang, Y., Qian, C., Wei, J., Xing, Y., & Bai, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746647 · Cited by 77 · see citing works
Ponziani, F. R., De Luca, A., Picca, A., Marzetti, E., Petito, V., Del Chierico, F., Reddel, S., Paroni Sterbini, F., Sanguinetti, M., Putignani, L., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1905 · Cited by 77 · see citing works
Lu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 73 · see citing works
Self-citationManipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69 · see citing works
Self-citationLiu, W., Ma, F., Sun, B., Liu, Y., Tang, H., Luo, J., Chen, H., & Luo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756872 · Cited by 65 · see citing works
Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy
Zhang, X., Liu, Q., Liao, Q., & Zhao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.37445 · Cited by 65 · see citing works
Self-citationInamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 62 · see citing works
Dóra, D., Ligeti, B., Kovács, T., Revisnyei, P., Gálffy, G., Dulka, E., Krizsán, D., Kalcsevszki, R., Megyesfalvi, Z., Döme, B., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204746 · Cited by 61 · see citing works
Dutta, D., & Lim, S. H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00211-6 · Cited by 58 · see citing works
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 60 · see citing works
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Wang, L., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106088 · Cited by 59 · see citing works
Dinh, N. T. M., Nguyen, T. M., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020717 · Cited by 58 · see citing works
Integrating the Tumor Microenvironment into Cancer Therapy
Sanegre, S., Lucantoni, F., Burgos‐Panadero, R., de la Cruz‐Merino, L., Noguera, R., & Naranjo, T. Á. (2020) · Cancers · doi:10.3390/cancers12061677 · Cited by 57 · see citing works
Huang, C.-L., Li, M., Liu, B., Zhu, H., Dai, Q., Fan, X., Mehta, K. D., Huang, C. H., Neupane, P. C., Wang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642110 · Cited by 56 · see citing works
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 59 · see citing works
Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R., & ElRakaiby, M. T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530216 · Cited by 53 · see citing works
Han, L., Zhang, H., Chen, S., Zhou, L., Li, Y., Zhao, K., Huang, F., Fan, Z., Xuan, L., Zhang, X., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.006 · Cited by 53 · see citing works
Self-citationGut microbiome and CAR-T therapy
Abid, M. B., Shah, N. N., Maatman, T. C., & Hari, P. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0155-8 · Cited by 53 · see citing works
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
Wang, G., He, X., & Wang, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188846 · Cited by 51 · see citing works
Autism spectrum disorder is associated with gut microbiota disorder in children
Sun, H., You, Z., Jia, L., & Wang, F. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1896-6 · Cited by 52 · see citing works
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Zhang, J., Wu, K.-H., Shi, C., & Li, G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01027-2 · Cited by 50 · see citing works
Self-citationSun, Y., Yang, Q., Shen, J., Wei, T., Shen, W., Zhang, N., Luo, P., & Zhang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745859 · Cited by 46 · see citing works
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
Yang, B., Liu, T., Qu, Y., Liu, H., Zheng, S. G., Cheng, B., & Sun, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00563 · Cited by 46 · see citing works
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 45 · see citing works
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 50 · see citing works
Self-citationImmunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 47 · see citing works
Entezam, M., Sanaei, M., Mirzaei, Y., Mer, A. H., Abdollahpour‐Alitappeh, M., Azadegan‐Dehkordi, F., & Bagheri, N. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121459 · Cited by 44 · see citing works
Long, L. L., Svenson, K. L., Mourino, A. J., Michaud, M., Fahey, J. R., Waterman, L., Vandegrift, K. L., & Adams, M. D. (2021) · Lab Animal · doi:10.1038/s41684-021-00777-0 · Cited by 42 · see citing works
Kim, J. H., Ahn, B., Hong, S., Jung, H., Kim, D. H., Choi, K. D., Ahn, J. Y., Lee, J. H., Na, H. K., Kim, J. H., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1198 · Cited by 42 · see citing works
Stamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 41 · see citing works
Miglietta, F., Griguolo, G., Guarneri, V., & Dieci, M. V. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0197 · Cited by 39 · see citing works
Understanding asthma and allergies by the lens of biodiversity and epigenetic changes
Fiuza, B. S. D., Fonseca, H. F., Meirelles, P. M., Marques, C. R., da Silva, T. M., & Figueiredo, C. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623737 · Cited by 38 · see citing works
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
Rodallec, A., Sicard, G., Fanciullino, R., Benzekry, S., Lacarelle, B., Milano, G. A., & Ciccolini, J. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1540588 · Cited by 38 · see citing works
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 37 · see citing works
Jantz-Naeem, N., Loschinski, R., Borucki, K., Mitchell-Flack, M., Böttcher, M., Schraven, B. L., Mougiakakos, D., & Kahlfuß, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1060112 · Cited by 35 · see citing works
Gut bacteria formation and influencing factors
Yang, J., Wu, J., Li, Y., Zhang, Y., Cho, W. C. S., Ju, X., van Schothorst, E. M., & Zheng, Y. (2021) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiab043 · Cited by 35 · see citing works
Xu, H., Xu, X., Wang, H., Ge, W., & Cao, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102909 · Cited by 32 · see citing works
Self-citationTyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
Li, X., Lin, Y., Li, X., Xu, X., Zhao, Y., Xu, L., Gao, Y., Li, Y., Tan, Y., Qian, P., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103048 · Cited by 34 · see citing works
The role of gut microbiota in immune checkpoint inhibitor therapy
Yi, M., Qin, S., Chu, Q., & Wu, K. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.11.12 · Cited by 32 · see citing works
Self-citationSphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
Lau, P., Zhang, G., Zhao, S., Liang, L., Zhang, H., Zhou, G., Hung, M., Chen, X., & Liu, H. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00911-z · Cited by 30 · see citing works
Race, the microbiome and colorectal cancer
Royston, K. J., Adedokun, B., & Olopade, O. I. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.773 · Cited by 30 · see citing works
Lu, P., Tsai, T., Chang, J. W., Deng, S., & Cheng, C. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13298 · Cited by 30 · see citing works
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29 · see citing works
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Yavuz, B. G., Datar, S. S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M. B., Lee, S. S., Hu, Z. I., Koay, E. J., Cao, H. S. T., Jalal, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15194875 · Cited by 28 · see citing works
Brown, S.-A. N., Ray, J. C., & Herrmann, J. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09992-5 · Cited by 28 · see citing works
Microbiome as a Target for Cancer Therapy
Suraya, R., Nagano, T., Kobayashi, K., & Nishimura, Y. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420920721 · Cited by 27 · see citing works
Inchingolo, A. M., Malcangi, G., Piras, F., Palmieri, G., Settanni, V., Riccaldo, L., Morolla, R., Buongiorno, S., de Ruvo, E., Inchingolo, A. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060933 · Cited by 30 · see citing works
RetractedMetformin as a booster of cancer immunotherapy
Panaampon, J., Zhou, Y., & Saengboonmee, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110528 · Cited by 27 · see citing works
The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
Alkharabsheh, O. A., Sidiqi, M. H., Aljama, M. A., Gertz, M. A., & Frankel, A. E. (2019) · Acta Haematologica · doi:10.1159/000500976 · Cited by 27 · see citing works
Borgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10457-y · Cited by 29 · see citing works
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martı́n-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 25 · see citing works
Gut microbiota-mediated tributyltin-induced metabolic disorder in rats
Yuan, G., Zhang, Z., Gao, X., Zhu, J., Guo, W., Wang, L., Ding, P., Jiang, P., & Li, L. (2020) · RSC Advances · doi:10.1039/d0ra07502g · Cited by 25 · see citing works
PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
Hosseinzadeh, R., Feizisani, F., Shomali, N., Abdelbasset, W. K., Hemmatzadeh, M., Navashenaq, J. G., Jadidi‐Niaragh, F., Bokov, D. O., Janebifam, M., & Mohammadi, H. (2021) · IUBMB Life · doi:10.1002/iub.2558 · Cited by 25 · see citing works
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
Zhou, Y., Liu, Z., & Chen, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847350 · Cited by 25 · see citing works
Immune Checkpoints in Endometriosis—A New Insight in the Pathogenesis
Suszczyk, D., Skiba, W., Pawłowska, A., Dymanowska-Dyjak, I., Włodarczyk, K., Paduch, R., & Wertel, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116266 · Cited by 23 · see citing works
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 23 · see citing works
Frąk, M., Grenda, A., Krawczyk, P. A., Milanowski, J., & Kalinka‐Warzocha, E. (2022) · Cancers · doi:10.3390/cancers14225577 · Cited by 23 · see citing works
Geum, M. J., Kim, C., Kang, J. E., Choi, J. H., Kim, J. S., Son, E. S., Lim, S. M., & Rhie, S. J. (2021) · Pharmaceuticals · doi:10.3390/ph14050445 · Cited by 22 · see citing works
Microbiome modulation of tumorigenesis and immune responses
Chen, Y., Fang, Y., Lyu, Z., Tian, Y., Niu, S., Li, Y.-R., & Yang, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01208-9 · Cited by 26 · see citing works
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21 · see citing works
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 21 · see citing works
MDM2 inhibitors in cancer immunotherapy: Current status and perspective
Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 20 · see citing works
Zapata, M. E. S., Pellitero, A. M., Isla, D., Gálvez, E. H., Ruiz, M. G., Sesma, A., Barbero-Herranz, R., Galeano, J., del Campo, R., Ocáriz, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33684 · Cited by 20 · see citing works
Alshammari, K. M., Alotaibi, F., Alsugheir, F., Aldawoud, M., Alolayan, A. A. M., Algarni, M., Sabatin, F., Mohammad, M. F., Alosaimi, A., Sanai, F. M., et al. (2023) · Cancers · doi:10.3390/cancers16010133 · Cited by 19 · see citing works
Sun, L., Wang, X., Zhou, H., Li, R., Meng, M., Roviello, G., Oh, B., Feng, L., Yu, Z., & Wang, J. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1201 · Cited by 19 · see citing works
Zhou, H. P., Chen, Y., Yu, X., Wu, Q., Li, H., Li, Y., Su, G., Ke, L., Wu, J., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050721 · Cited by 18 · see citing works
Wang, L. (2021) · Current Research in Translational Medicine · doi:10.1016/j.retram.2021.103320 · Cited by 17 · see citing works
- Authors
- Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Chu, Qian
- Wu, Kongming
- Venue
- Journal of Hematology & Oncology
- Published
- 2018-03-27
- Volume
- 11
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5870075
- OpenAlex
- W2794616539
- Cited by
- 179
- References
- 110
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 17 · 2023: 23 · 2022: 32 · 2021: 26 · 2020: 24 · 2019: 26 · 2018: 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81572608 and 81172422, 81672984)
- Wuhan Science and Technology Bureau (2017060201010170)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- gut microbiota, immune checkpoint inhibitors, immunotherapy efficacy, cancer immunotherapy, treatment resistance, predictive biomarkers, commensal bacteria, anticancer mechanism, microbiome manipulation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
